Current Edition

Expanding the treatment arsenal
Volume 11 Issue 1

Expanding the Treatment Arsenal for Chronic Hepatitis B

Significant public health issues invariably arise, but the trajectory is not always obvious. Deborah Komlos of Clarivate discusses how such has been the case for …

Continue Reading →
Addressing the challenges of clinical
Volume 11 Issue 1

Addressing the Challenges of Clinical Trials Insurance

Often thought of as a simple off-the-shelf product, clinical trials insurance can be considerably more complex, as Victoria Cockayne and Johannes Klose of Allianz explain. …

Continue Reading →
Are graph database the key ingredient AI
Volume 11 Issue 1

Are Graph Databases the Key Ingredient AI is Missing in Drug Discovery?

The drug discovery process is hugely data-intensive, making it an ideal application for artificial intelligence (AI) and machine learning. But it isn’t as straightforward as …

Continue Reading →
Strategic advantages of integrating regulators
Volume 11 Issue 1

Strategic Advantages of Integrating Regulators’ Advice into Clinical Trial Programme Design

Working closely with regulators should be seen as an important strategy for successful drug development, rather than a barrier to be sidestepped or overcome. Early …

Continue Reading →
Advancing heart failure research
Volume 11 Issue 1

Advancing Heart Failure Research Through Innovative Clinical Trial Design

Cardiovascular disease remains public enemy number one in healthcare. Taking the top spot on the mortality scale, diseases of the heart are predicted to affect …

Continue Reading →
Clinical trial packaging
Volume 11 Issue 1

Clinical Trial Packaging: Considerations and Challenges

Colin Newbould of Wasdell talks through the vital considerations when packaging drugs for clinical supply. He discusses the various challenges presented by blinding, randomisation and …

Continue Reading →
Adjudication in clinical trials
Volume 11 Issue 1

Adjudication in Clinical Trials: A Primer

Although the main purpose of most clinical trials is to compare the efficacy and/or safety endpoints that occur in two groups, the endpoint management and …

Continue Reading →
A unique model to accelerate industry-sponsored
Volume 11 Issue 1

A Unique Model to Accelerate Industry-sponsored Research in Malaysia

The influx of industry-sponsored research (ISR) into the Asia Pacific region is continually growing due to the rising costs and complicated processes involved in drug …

Continue Reading →
Gaps and challenges in malaria clinical research
Volume 11 Issue 1

Gaps and Challenges in Malaria Clinical Research and Development

Malaria has been a major global health problem of humans throughout history and is a leading cause of death and disease across many tropical and …

Continue Reading →
Improving patient outcomes
Volume 11 Issue 1

Improving Patient Outcomes: eCOA Steps up in the Fight Against Cancer

By developing and bringing new oncology treatments to market, clinical researchers have an important role to play in helping reduce cancer-related mortality. But trials in …

Continue Reading →